SESN Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Sesen Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$0.96 |
| 52 Week Low | US$0.36 |
| Beta | 0.86 |
| 1 Month Change | 0.082% |
| 3 Month Change | 11.87% |
| 1 Year Change | -16.68% |
| 3 Year Change | -32.97% |
| 5 Year Change | -28.74% |
| Change since IPO | -94.38% |
Recent News & Updates
Recent updates
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Shareholder Returns
| SESN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | 0.8% | 2.8% |
| 1Y | -16.7% | 7.1% | -9.2% |
Return vs Industry: SESN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: SESN underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| SESN volatility | |
|---|---|
| SESN Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SESN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SESN's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | https://sesenbio.com |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
| SESN fundamental statistics | |
|---|---|
| Market Cap | US$123.68m |
| Earnings (TTM) | -US$3.37m |
| Revenue (TTM) | US$60.00m |
2.1x
P/S Ratio-36.7x
P/E RatioIs SESN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SESN income statement (TTM) | |
|---|---|
| Revenue | US$60.00m |
| Cost of Revenue | US$25.31m |
| Gross Profit | US$34.69m |
| Other Expenses | US$38.05m |
| Earnings | -US$3.37m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 57.81% |
| Net Profit Margin | -5.61% |
| Debt/Equity Ratio | 0% |
How did SESN perform over the long term?
See historical performance and comparison